In a proportion of cancer patients, tolerance to TIF1γ may be disrupted, with the subsequent appearance of anti-TIF1γ antibodies in serum, which may cross-react with TIF1γ synthesized in skin or skeletal muscle [44]. Here, TRIM33 is linked to cancer.